Company News: Gilead Sciences, Cubist Pharmaceuticals and Calixa Therapeutics

Share this article:
Gilead Sciences said that it will likely end development of darusentan, a once promising endothelin receptor antagonist for treating resistant hypertension, because the agent did not achieve its co-primary endpoints in a phase III trial.

Cubist Pharmaceuticals said it plans to acquire privately held Calixa Therapeutics for $92.5 million in cash and up to $310 million in milestone payments. In the deal, expected to close by year's end, Cubist would obtain Calixa's rights to develop and commercialize the firm's Phase 2 antibiotic CXA-201, which is intended to treat common, serious Gram-negative infections.
Share this article:

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.